ScholarIQanswers from OpenAlex

Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease

PaperCitations, authors & open-access status

Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease have?

ScholarIQcitation count

Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease has 292 citations in the OpenAlex counts ScholarIQ stores.

When was Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease published?

ScholarIQyear

Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease has 2001 year in the ScholarIQ index.

What is the open-access status of Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease?

ScholarIQoa status

Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease has closed oa status in the ScholarIQ index.

What is the DOI of Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease?

ScholarIQdoi

The DOI for Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease is on the source record.

What is the PMID of Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease?

ScholarIQpmid

The PMID for Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease is on the source record.

What is the OpenAlex record for Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease?

ScholarIQopenalex

The OpenAlex for Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial